MYD88-gene mutation and increased interleukin-10 (IL-10) levels in CSF have been observed in PCNSL, and they show promising sensitivity (94–98%) and specificity (98–99%) for both newly diagnosed and recurring PCNSL [80,81]. This evidence concerns the gene IL10 and primary central nervous system lymphoma.